230 related articles for article (PubMed ID: 10194100)
1. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.
Paterson DL; Singh N; Gayowski T; Marino IR
Clin Infect Dis; 1999 Mar; 28(3):683-4. PubMed ID: 10194100
[No Abstract] [Full Text] [Related]
2. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
[No Abstract] [Full Text] [Related]
4. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
[TBL] [Abstract][Full Text] [Related]
5. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
[No Abstract] [Full Text] [Related]
6. Escherichia coli ST131 producing extended-spectrum β-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options.
Mantengoli E; Luzzaro F; Pecile P; Cecconi D; Cavallo A; Attala L; Bartoloni A; Rossolini GM
Clin Infect Dis; 2011 Mar; 52(5):690-1. PubMed ID: 21220769
[No Abstract] [Full Text] [Related]
7. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
[TBL] [Abstract][Full Text] [Related]
8. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
[TBL] [Abstract][Full Text] [Related]
10. First case of New Delhi metallo-beta-lactamase 1-producing Escherichia coli infection in Japan.
Chihara S; Okuzumi K; Yamamoto Y; Oikawa S; Hishinuma A
Clin Infect Dis; 2011 Jan; 52(1):153-4. PubMed ID: 21148536
[No Abstract] [Full Text] [Related]
11. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli from India.
Bhattacharjee A; Sen MR; Anupurba S; Prakash P; Nath G
J Antimicrob Chemother; 2007 Sep; 60(3):703-4. PubMed ID: 17623688
[No Abstract] [Full Text] [Related]
12. Molecular characterization of plasmids encoding CTX-M-15 extended-spectrum beta-lactamase associated with the ST131 Escherichia coli clone in Belgium.
Montesinos I; Rodriguez-Villalobos H; De Mendonça R; Bogaerts P; Deplano A; Glupczynski Y
J Antimicrob Chemother; 2010 Aug; 65(8):1828-30. PubMed ID: 20534625
[No Abstract] [Full Text] [Related]
13. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
14. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
15. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
[TBL] [Abstract][Full Text] [Related]
17. Community-acquired extended-spectrum beta-lactamase producers, United States.
Doi Y; Adams J; O'Keefe A; Quereshi Z; Ewan L; Paterson DL
Emerg Infect Dis; 2007 Jul; 13(7):1121-3. PubMed ID: 18214201
[No Abstract] [Full Text] [Related]
18. Susceptibility pattern of extended-spectrum beta-lactamase producing bacteria isolated from inpatients to five antimicrobial drugs in a community hospital in Northern Israel.
Colodner R; Raz R; Chazan B; Sakran W
Int J Antimicrob Agents; 2004 Oct; 24(4):409-10. PubMed ID: 15380271
[No Abstract] [Full Text] [Related]
19. Dissemination of extended-spectrum β-lactamase-producing Escherichia coli at home: a potential occupational hazard for healthcare workers?
Cotter M; Boyle F; Khan A; Boo TW; O'Connell B
J Hosp Infect; 2012 Jan; 80(1):100-1. PubMed ID: 22112534
[No Abstract] [Full Text] [Related]
20. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
